OncoSil Medical Ltd (ASX: OSL) Share Price and News

Mr Hall is a London-based Australian financier, media proprietor and philanthropist. He founded investment firm Hunter Hall Investment Management in 1993, and acted as Chief Investment Officer and Executive Chairman during his 23 year tenure.

Mr Lange brings with him over 30 years of experience in the medical devices industry. Since 2003, Nigel has held leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and the Middle East. Since 2017, Nigel served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, Nigel has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. He is Member of the Risk Committee.

Dr Duthy brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX). Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, and has been involved in M&A transactions. He currently advises Mayne Pharma (ASX:MYX) and serves as a Non-Executive Director of Invex Therapeutics (ASX:IXC).

Mr Cubbin is an experienced biopharmaceutical executive with over 30 years' experience in senior executive, CFO, Director and Chair roles, across industries. During his tenure as Group Chief Financial Officer at Telix Pharmaceuticals Limited, a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, he was a member of the team which completed the IPO, raised $270 million in capital and grew the business to a multi-billion dollar market capitalisation. Mr Cubbin has also served as Chairman of various boards, including Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine. He is member of Risk Committee.

Ms Smits brings a expertise in governance, strategy, risk oversight, and corporate communications, with a career advising over 500 ASX-listed management teams and Boards. Since 2021, she has served as a Director on the Board of Australian Shareholders Association. Her career began as a finance journalist, including roles as a foreign correspondent in New York, reporting from inside the New York Stock Exchange on Wall Street. With experience in the financial markets and corporate affairs, Ms Smits has contributed to entrepreneurial ventures and Boards, enhancing their governance and strategic direction.

-

-